Pharmacogenomics and personalized medicine: Wicked problems, ragged edges and ethical precipices

New Biotechnology

Volumn 29, Issue 6, 2012, Pages 757-768

  Fleck, Leonard M ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER DRUG; ETHICAL ISSUES; ETHICAL QUESTION; ETHICAL THEORIES; GENETIC TESTING; LIFE EXPECTANCIES; PERSONALIZED MEDICINES; PHARMACOGENOMICS; PREMATURE DEATH; TARGETED CANCER THERAPY; WICKED PROBLEMS;

DISEASES;

PHILOSOPHICAL ASPECTS;

BEVACIZUMAB; CETUXIMAB;

ALZHEIMER DISEASE; ARTHRITIS; ARTICLE; ARTIFICIAL HEART; BREAST CANCER; CARDIOVASCULAR MORTALITY; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; HEALTH CARE COST; HEALTH CARE NEED; HEALTH CARE ORGANIZATION; HEART DISEASE; HEART FAILURE; KIDNEY FAILURE; LEFT VENTRICULAR ASSIST DEVICE; LIFE EXPECTANCY; LUNG NON SMALL CELL CANCER; MEDICAL TECHNOLOGY; MEDICARE; NATIONAL HEALTH INSURANCE; NEOPLASM; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PESSIMISM; PHARMACOGENOMICS; PRIORITY JOURNAL; QUALITY OF LIFE; STROKE; UNITED STATES;

HEALTH CARE COSTS; HEALTH CARE RATIONING; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS;

EID: 84865442326     PISSN: 18716784     EISSN: 18764347     Source Type: Journal    
DOI: 10.1016/j.nbt.2012.03.002     Document Type: Article

References (53)

1. Chen P., et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N. Engl. J. Med. 2011, 364:1126-1133.
2. Link E., et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N. Engl. J. Med. 2008, 359:789-799.
3. Whyte KP, Thompson PB. (2011) Ideas for how to take wicked problems seriously. J. Agric. Environ. Ethics (e-published ahead of print, 11/20/11 ). http://www.springerlink.com.proxy2.cl.msu.edu/content/k3582206v1688261/fulltext.pdf.
4. Callahan D. What Kind of Life: The Limits of Medical Progress 1990, Simon and Schuster, (chap. 2: On the ragged edge: needs, endless needs).
5. Fojo T., Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J. Natl. Cancer Inst. 2009, 101:1044-1048.
6. Rittel H.W., Webber M.M. Dilemmas in a general theory of planning. Policy Sci. 1973, 4:155-169.
7. Hillner B.E., Smith T.J. Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing. J. Clin. Onc. 2009, 27:2111-2113.
8. Fleck L.M. Just Caring: Health Care Rationing and Democratic Deliberation 2009, Oxford University Press.
9. Lloyd-Jones D., et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 2010, 121:e46-e215.
10. Truffer C.J., et al. Health spending projections through 2019: the recession's impact continues. Hlth. Aff. 2010, 29:522-529.
11. Thorpe K.E., Howard D.H. The rise in spending among medicare beneficiaries: the role of chronic disease prevalence and changes in treatment intensity. Hlth. Aff. 2006, 25:w378-w388.
12. Siegel R., et al. Cancer Statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 2011, 61:212-236.
13. Malvezzi M., et al. European cancer mortality predictions for the year 2011. Ann. Onc. 2011, 22:947-956.
14. Fojo T., Parkinson D.R. Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much?. Clin. Cancer Res. 2010, 16:5972-5980.
15. Nadler E., et al. Do oncologists believe new cancer drugs offer good value?. Oncologist 2006, 11:90-95.
16. Lichtenberg F.R. Despite steep costs, payments for new cancer drugs make economic sense. Nat. Med. 2011, 17:244.
17. Lichtenberg F.R. The effect of new cancer drug approvals on life expectancy of American cancer patients, 1978-2004. Econ. Innov. New Technol. 2009, 18:407-428.
18. Pirker R., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomized phase III trial. Lancet 2009, 373:1525-1531.
19. Lynch T.J., et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J. Clin. Oncol. 2010, 28:911-917.
20. MacReady N. The climbing costs of cancer care. J. Natl. Cancer. Inst. 2011, 103:1433-1435.
21. Shepard F.A. Maintenance therapy comes of age for non-small-cell lung cancer, but at what cost?. J. Clin. Oncol. 2011, 29:4068-4070.
22. Elkin E.B., Bach P.B. Cancer's next frontier: addressing high and increasing costs. JAMA 2010, 303:1086-1087.
23. Cohen J., Looney W. What is the value of oncology medicines?. Nat. Biotechnol. 2010, 28:1160-1163.
24. Meropol N.J., et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J. Clin. Oncol. 2009, 27:3868-3874.
25. Coate L.E., Leighl N.B. How affordable are targeted therapies in non-small cell lung cancer?. Curr. Treat. Opt. Oncol. 2011, 12:1-11.
26. Ramsey S.D. Economics and the new generation of targeted therapies for non-small cell lung cancer. J. Natl. Cancer Inst. 2010, 102:287-288.
27. Howard D.H., et al. The value of new chemotherapeutic agents for metastatic colorectal cancer. Arch. Intern. Med. 2010, 170:537-542.
28. Konski A. The war on cancer: progress at what price?. J. Clin. Oncol. 2011, 29:1503-1504.
29. Sulmasy D.P. Cancer care, money, and the value of life: whose justice? Which rationality?. J. Clin. Oncol. 2007, 25:217-222.
30. Slatore C.G., et al. An official American Thoracic Society systematic review: insurance status and disparities in lung cancer practices and outcomes. Am. J. Respir. Crit. Car. Med. 2010, 182:1195-1205.
31. Druker B.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New Engl. J. Med. 2001, 344:1031-1037.
32. Sawyers C.L. Even better kinase inhibitors for chronic myeloid leukemia. New Engl. J. Med. 2010, 362:2314-2315.
33. Kantarjian H., et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 2010, 362:2260-2270.
34. Barrett A., et al. How much will Herceptin really cost?. BMJ 2006, 333:1118-1120.
35. Schneider B.P., et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG2100. J. Clin. Oncol. 2008, 26:4672-4678.
36. Harris J. The Value of Life 1985, Routledge and Kegan Paul.
37. Anonymous The Avastin denial: a chillingly blunt assertion of regulatory power against a drug for breast cancer. Wall Street J. 2011, (Nov. 19), on-line opinion.
38. Nocera J. Why doesn't no mean no?. New York Times 2011, (Nov. 21), opinion. http://www.nytimes.com/2011/11/22/opinion/why-doesnt-no-mean-no.html? (Last accessed 1.12.12).
39. Ruzzo A., et al. Molecular predictors of efficacy to anti-EFGR agents in colorectal cancer patients. Curr. Cancer Drug Targets 2010, 10:68-79.
40. th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. Ann. Oncol. 2010, 21(Suppl. 6):vi1-vi10.
41. Blanke C.D., et al. KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice. Oncologist 2011, 16:1061-1068.
42. Ortega J., et al. Current progress in targeted therapy for colorectal cancer. Cancer Control 2010, 17:7-15.
43. Gawande A. Letting go: what should medicine do when it can't save your life?. New Yorker 2010, 36-51.
44. Kwok A.C., et al. The intensity and variation of surgical care at the end of life: a retrospective cohort study. Lancet 2011, 378:1408-1413.
45. Pevtzow L. Aging out of health care? Ever-increasing costs prompt some doctors to ask if a patient can be too old for a lifesaving but expensive procedure. Chicago Tribune 2011, (Nov. 30). http://www.chicagotribune.com/health/ct-x-surgery-for-old-20111130,0,3225217,print.story (Accessed 03.12.11).
46. Forman D.E., et al. Cardiac care for older adults: time for a new paradigm. J. Am. Coll. Cardiol. 2011, 57:1801-1810.
47. Fleck L.M. Just caring: health care rationing, terminal illness, and the medically least well off. J. Law Med. Ethics 2011, 39:156-171.
48. Wagstaff A. Health rationing in Europe: can cancer get a fair hearing?. Cancer World 2009, 24-31.
49. Daniels N. Just Health: Meeting Health Needs Fairly 2008, Cambridge University Press, Cambridge, pp. 11-78.
50. Temel J.S., et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N. Engl. J. Med. 2010, 363:733-742.
51. Rawls J. Political Liberalism 1993, Columbia University Press, New York.
52. Lancet Oncology Commission Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011, 12:933-980.
53. Wilking N., et al. Comparator Report on Patient Access to Cancer Drugs in Europe 2009, Karolinska Institute and Stockholm School of Economics.